Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.28
MNKD's Cash to Debt is ranked lower than
51% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. MNKD: 0.28 )
MNKD' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.28

F-Score: 4
Z-Score: -10.37
M-Score: -0.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROA (%) -74.04
MNKD's ROA (%) is ranked higher than
55% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. MNKD: -74.04 )
MNKD' s 10-Year ROA (%) Range
Min: -196.87   Max: -42.71
Current: -74.04

-196.87
-42.71
ROC (Joel Greenblatt) (%) -95.95
MNKD's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. MNKD: -95.95 )
MNKD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -285.33   Max: -72.81
Current: -95.95

-285.33
-72.81
EBITDA Growth (%) -27.20
MNKD's EBITDA Growth (%) is ranked higher than
60% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. MNKD: -27.20 )
MNKD' s 10-Year EBITDA Growth (%) Range
Min: -43   Max: 10.9
Current: -27.2

-43
10.9
EPS Growth (%) -24.70
MNKD's EPS Growth (%) is ranked higher than
65% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. MNKD: -24.70 )
MNKD' s 10-Year EPS Growth (%) Range
Min: -42.9   Max: 7.6
Current: -24.7

-42.9
7.6
» MNKD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

MNKD Guru Trades in Q1 2013

Jim Simons 1,354,116 sh (New)
Jean-Marie Eveillard Sold Out
» More
Q2 2013

MNKD Guru Trades in Q2 2013

Steven Cohen 212,767 sh (New)
Jim Simons Sold Out
» More
Q3 2013

MNKD Guru Trades in Q3 2013

Murray Stahl 57,451 sh (New)
Steven Cohen 231,900 sh (+8.99%)
» More
Q4 2013

MNKD Guru Trades in Q4 2013

Murray Stahl 106,211 sh (+84.87%)
Steven Cohen 143,117 sh (-38.29%)
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 Sold Out 0.01%$2.31 - $3.56 $ 6.28128%0
Jean-Marie Eveillard 2012-12-31 New Buy0.01%$1.85 - $2.83 $ 6.28191%800000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT 33.30
MNKD's EV-to-EBIT is ranked lower than
62% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. MNKD: 33.30 )
MNKD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 33.3

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) -40.73
MNKD's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. MNKD: -40.73 )
MNKD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.7   Max: 54
Current: -40.73

-2.7
54

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NNF1.Germany
MannKind Corporation, a development stage biopharmaceutical company, was founded in 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The Company also develops MKC1106-MT, an investigational cancer immunotherapy product, which is in Phase II clinical trials; and MKC204, which is in preclinical development stage for the treatment of malignancies and inflammatory diseases.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide